GlassScriptPhysician profile
Gary D Ratliff
NPI 1902888274
$2,882.28
in general payments reported to CMS, 2019-2025
38 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $369 · 2021: $387 · 2022: $367 · 2023: $601 · 2024: $437 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,382.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $362.02 | 2021-2025 | |
| Pfizer INC. | $324.98 | 2020-2025 | |
| Glaxosmithkline, LLC. | $230.75 | 2019-2024 | Shingrix |
| Gilead Sciences, INC. | $217.15 | 2024-2025 | Biktarvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.29 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $211.38 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $149.88 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $139.97 | 2019-2024 | Spravato, Xarelto |
| Medtronic, INC. | $93.58 | 2022-2025 | Inceptiv |
| Sanofi-Aventis U.S. LLC | $76.60 | 2019-2023 | |
| Amgen INC. | $75.69 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $70.64 | 2019-2022 | |
| Dexcom, INC. | $69.69 | 2023-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $66.75 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $63.15 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Ratliff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.